Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305145 · ClinicalTrials.gov registry record · Phase 2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
A Phase 2 study of Melanoma Stage IV and Melanoma Stage III, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 2
- Study locations
NCT04305145 is a Phase 2 study of Melanoma Stage IV and Melanoma Stage III that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 42 participants, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04305145, a Phase 2 study of Melanoma Stage IV and Melanoma Stage III, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patients treated with infliximab experience steroid-free disease resolution after 7 weeks? * How many patients treated with steroids experience steroid-free disease resolution after 7 weeks?
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Methylprednisolone
- DRUG Infliximab
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305145
The ClinicalTrials.gov registry entry for NCT04305145 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 17 other Melanoma Stage IV trials with a reported enrollment target (58% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Melanoma Stage IV appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.
NCT04305145 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04305145 about?
NCT04305145 is a clinical study titled "Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis". The goal of this clinical trial is to compare the safety and effectiveness of infliximab compared to steroids for the treatment of immune checkpoint inhibitor-induced colitis (ICI colitis) in patients with stage III/IV skin cancer. The main questions this study aims to answer are: * How many patie...
What is the current status of trial NCT04305145?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2020-08-31. Estimated completion is 2030-06-30.
What conditions does trial NCT04305145 study?
This clinical trial studies the following conditions: Melanoma Stage IV, Melanoma Stage III, Drug Toxicity, Skin Cancer Stage III, Skin Cancer Stage IV.
What interventions are being tested in trial NCT04305145?
The interventions under investigation include: Prednisone (DRUG), Methylprednisolone (DRUG), Infliximab (DRUG).
Who is sponsoring clinical trial NCT04305145?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305145 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma Stage IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
RECRUITING · Phase 2
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RECRUITING · Phase 2
-
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.